CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05150236
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:24.900406+00:00
Published At: 2023-12-15T00:00:00+00:00
Record Updated At: 2023-12-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Prostatic Neoplasms", "Genital Neoplasms, Male", "Urogenital Neoplasms", "Prostate Cancer", "Neoplasms by Site", "Neoplasms", "Prostatic Disease"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-12-15"
protocolSection.identificationModule.nctId: "NCT05150236"
protocolSection.identificationModule.officialTitle: "Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC)"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.